| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| β-内酰胺类抗菌药(元) | 975,915,065.89 | 499,940,035.99 | 779,273,636.57 | 367,382,633.79 |
| 抗胆碱药和合成解痉药(元) | - | - | - | 62,326,942.71 |
| 喹喏酮类抗菌药(元) | - | - | - | 51,932,582.71 |
| 抗胆碱和合成解痉药(元) | 159,677,114.41 | 66,222,071.52 | 164,679,191.62 | 62,326,942.71 |
| 喹喏酮类原料药及中间体(元) | - | 56,078,742.73 | - | 51,932,582.71 |
| 皮肤用抗真菌药(元) | 77,032,691.41 | 27,953,344.14 | 72,609,682.34 | 27,433,671.34 |
| 喹诺酮类抗菌药(元) | 97,063,031.59 | - | 104,753,538.12 | - |
| 其他主营业务(元) | - | - | - | 27,433,671.34 |
| 其他产品(元) | 40,902,655.80 | 20,993,073.72 | 52,964,706.23 | 23,715,744.04 |
| 其他业务(元) | - | - | - | 2,544,054.05 |
| 营业成本(元) | ||||
| β-内酰胺类抗菌药(元) | 773,093,794.66 | - | 686,170,001.30 | - |
| 抗胆碱药和合成解痉药(元) | - | - | - | - |
| 喹喏酮类抗菌药(元) | - | - | - | - |
| 抗胆碱和合成解痉药(元) | 75,454,795.65 | - | 83,830,658.40 | - |
| 喹喏酮类原料药及中间体(元) | - | - | - | - |
| 皮肤用抗真菌药(元) | 41,421,249.74 | - | 36,598,782.96 | - |
| 喹诺酮类抗菌药(元) | 87,661,229.09 | - | 83,886,362.56 | - |
| 其他主营业务(元) | - | - | - | - |
| 其他产品(元) | 17,189,014.76 | - | 19,672,916.37 | - |
| 其他业务(元) | - | - | - | 106,498.58 |
| 毛利(元) | ||||
| β-内酰胺类抗菌药(元) | 202,821,271.23 | - | 93,103,635.27 | - |
| 抗胆碱药和合成解痉药(元) | - | - | - | - |
| 喹喏酮类抗菌药(元) | - | - | - | - |
| 抗胆碱和合成解痉药(元) | 84,222,318.76 | - | 80,848,533.22 | - |
| 喹喏酮类原料药及中间体(元) | - | - | - | - |
| 皮肤用抗真菌药(元) | 35,611,441.67 | - | 36,010,899.38 | - |
| 喹诺酮类抗菌药(元) | 9,401,802.50 | - | 20,867,175.56 | - |
| 其他主营业务(元) | - | - | - | - |
| 其他产品(元) | 23,713,641.04 | - | 33,291,789.86 | - |
| 其他业务(元) | - | - | - | 2,437,555.47 |
| 毛利率(%) | ||||
| β-内酰胺类抗菌药(%) | 20.78 | - | 11.95 | - |
| 抗胆碱药和合成解痉药(%) | - | - | - | - |
| 喹喏酮类抗菌药(%) | - | - | - | - |
| 抗胆碱和合成解痉药(%) | 52.75 | - | 49.09 | - |
| 喹喏酮类原料药及中间体(%) | - | - | - | - |
| 皮肤用抗真菌药(%) | 46.23 | - | 49.60 | - |
| 喹诺酮类抗菌药(%) | 9.69 | - | 19.92 | - |
| 其他主营业务(%) | - | - | - | - |
| 其他产品(%) | 57.98 | - | 62.86 | - |
| 其他业务(%) | - | - | - | 95.81 |
| 收入构成(%) | ||||
| β-内酰胺类抗菌药(%) | 72.26 | 74.49 | 66.36 | 54.26 |
| 抗胆碱药和合成解痉药(%) | - | - | - | 9.21 |
| 喹喏酮类抗菌药(%) | - | - | - | 7.67 |
| 抗胆碱和合成解痉药(%) | 11.82 | 9.87 | 14.02 | 9.21 |
| 喹喏酮类原料药及中间体(%) | - | 8.36 | - | 7.67 |
| 皮肤用抗真菌药(%) | 5.70 | 4.16 | 6.18 | 4.05 |
| 喹诺酮类抗菌药(%) | 7.19 | - | 8.92 | - |
| 其他主营业务(%) | - | - | - | 4.05 |
| 其他产品(%) | 3.03 | 3.13 | 4.51 | 3.50 |
| 其他业务(%) | - | - | - | 0.38 |
| 毛利构成(%) | ||||
| β-内酰胺类抗菌药(%) | 57.01 | - | 35.25 | 0.00 |
| 抗胆碱药和合成解痉药(%) | - | - | - | 0.00 |
| 喹喏酮类抗菌药(%) | - | - | - | 0.00 |
| 抗胆碱和合成解痉药(%) | 23.67 | - | 30.61 | 0.00 |
| 喹喏酮类原料药及中间体(%) | - | - | - | 0.00 |
| 皮肤用抗真菌药(%) | 10.01 | - | 13.63 | 0.00 |
| 喹诺酮类抗菌药(%) | 2.64 | - | 7.90 | - |
| 其他主营业务(%) | - | - | - | 0.00 |
| 其他产品(%) | 6.67 | - | 12.60 | 0.00 |
| 其他业务(%) | - | - | - | 100.00 |